Assessment of AI Program 'DRISTi' as a Screening Tool
NCT07222293
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetic Retinopathy (DR)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Artelus AI
- Last updated on ClinicalTrials.gov
- December 9, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 2
- New Century Ophthalmology - Oxford · Oxford, NC
- New Century Ophthalmology - Raleigh · Raleigh, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.